Defibrotide for the Treatment of Severe COVID-19
ConditionCovid19
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-100
SponsorBrigham and Women's Hospital
About this trial
The goal of this study is to evaluate the safety and feasibility of defibrotide in COVID-19 pneumonia.
Eligibility criteria
Qualifiers
Age ≥18 years.
Active COVID-19 infection confirmed by positive SARS-CoV-2 PCR.
Radiographic evidence of bilateral pulmonary infiltrates.
A life expectancy of at least 24 hours.
Disqualifiers
Clinically significant acute bleeding.
Concomitant use of thrombolytic therapy (e.g. t-PA).
Hemodynamic instability, defined as a requirement for >1 vasopressor agent for enrollment into cohort 1, and a requirement for >2 vasopressor agents for enrollment into cohort 2
Known allergy or hypersensitivity to DF.
Trial design
Treatments tested in this trial
- Defibrotide
Treatment groups
42 Participants
are divided into 1 treatment groupSponsors and collaborators
Brigham and Women's Hospital
Lead sponsor
Jazz Pharmaceuticals
Collaborator
Source ClinicalTrials.gov